Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 432

1.

Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing-remitting multiple sclerosis.

Miller A, Spada V, Beerkircher D, Kreitman RR.

Mult Scler. 2008 May;14(4):494-9. doi: 10.1177/1352458507085029. Epub 2008 Jan 21.

PMID:
18208875
[PubMed - indexed for MEDLINE]
2.

A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients.

Ford CC, Johnson KP, Lisak RP, Panitch HS, Shifronis G, Wolinsky JS; Copaxone Study Group.

Mult Scler. 2006 Jun;12(3):309-20.

PMID:
16764344
[PubMed - indexed for MEDLINE]
3.

Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial.

Johnson KP, Brooks BR, Ford CC, Goodman AD, Lisak RP, Myers LW, Pruitt AA, Rizzo MA, Rose JW, Weiner LP, Wolinsky JS.

Mult Scler. 2003 Dec;9(6):585-91.

PMID:
14664471
[PubMed - indexed for MEDLINE]
4.
5.

Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients.

Zwibel HL; Copolymer-1 Treatment Study Principal Investigators.

Acta Neurol Scand. 2006 Jun;113(6):378-86.

PMID:
16674604
[PubMed - indexed for MEDLINE]
6.

Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.

Meca-Lallana JE, de Mingo-Casado P, Amorin-Díaz M, Martínez-Navarro ML, Barreiro AF.

Clin Ther. 2010 Jun;32(6):1061-6. doi: 10.1016/j.clinthera.2010.06.005.

PMID:
20637960
[PubMed - indexed for MEDLINE]
7.

Long-term follow up of glatiramer acetate compassionate use in Belgium.

Sindic CJ, Seeldrayers P, Vande Gaer L, De Smet E, Nagels G, De Deyn PP, Medaer R, Guillaume D, D'Hooghe MB, Deville MC, Decoo D, Sadzot B, Van Landegem W, Strauven T, Pepin J, Merckx H, Caekebeke J, van der Tool MA.

Acta Neurol Belg. 2005 Jun;105(2):81-5.

PMID:
16076061
[PubMed - indexed for MEDLINE]
8.

Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data.

Johnson KP, Ford CC, Lisak RP, Wolinsky JS.

Acta Neurol Scand. 2005 Jan;111(1):42-7.

PMID:
15595937
[PubMed - indexed for MEDLINE]
9.

[Long-term effects of glatiramer acetate in multiple sclerosis].

Brochet B.

Rev Neurol (Paris). 2008 Nov;164(11):917-26. doi: 10.1016/j.neurol.2008.02.045. Epub 2008 May 16. French.

PMID:
18790510
[PubMed - indexed for MEDLINE]
10.

Comparison of glatiramer acetate (Copaxone) and interferon beta-1b (Betaferon) in multiple sclerosis patients: an open-label 2-year follow-up.

Flechter S, Vardi J, Pollak L, Rabey JM.

J Neurol Sci. 2002 May 15;197(1-2):51-5.

PMID:
11997066
[PubMed - indexed for MEDLINE]
12.

Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients.

Le Page E, Leray E, Taurin G, Coustans M, Chaperon J, Morrissey SP, Edan G.

J Neurol Neurosurg Psychiatry. 2008 Jan;79(1):52-6. Epub 2007 Sep 10.

PMID:
17846110
[PubMed - indexed for MEDLINE]
13.

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate.

Ford C, Goodman AD, Johnson K, Kachuck N, Lindsey JW, Lisak R, Luzzio C, Myers L, Panitch H, Preiningerova J, Pruitt A, Rose J, Rus H, Wolinsky J.

Mult Scler. 2010 Mar;16(3):342-50. doi: 10.1177/1352458509358088. Epub 2010 Jan 27.

PMID:
20106943
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis.

Earnshaw SR, Graham J, Oleen-Burkey M, Castelli-Haley J, Johnson K.

Appl Health Econ Health Policy. 2009;7(2):91-108. doi: 10.2165/11314900-000000000-00000.

PMID:
19731967
[PubMed - indexed for MEDLINE]
16.

Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials.

Martinelli Boneschi F, Rovaris M, Johnson KP, Miller A, Wolinsky JS, Ladkani D, Shifroni G, Comi G, Filippi M.

Mult Scler. 2003 Aug;9(4):349-55.

PMID:
12926839
[PubMed - indexed for MEDLINE]
17.

A longitudinal observational study of a cohort of patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate.

Debouverie M, Moreau T, Lebrun C, Heinzlef O, Brudon F, Msihid J.

Eur J Neurol. 2007 Nov;14(11):1266-74.

PMID:
17956447
[PubMed - indexed for MEDLINE]
18.

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group.

Johnson KP, Brooks BR, Ford CC, Goodman A, Guarnaccia J, Lisak RP, Myers LW, Panitch HS, Pruitt A, Rose JW, Kachuck N, Wolinsky JS.

Mult Scler. 2000 Aug;6(4):255-66.

PMID:
10962546
[PubMed - indexed for MEDLINE]
19.

Management of worsening multiple sclerosis with mitoxantrone: a review.

Fox EJ.

Clin Ther. 2006 Apr;28(4):461-74. Review.

PMID:
16750460
[PubMed - indexed for MEDLINE]
20.

Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis.

Vollmer T, Panitch H, Bar-Or A, Dunn J, Freedman MS, Gazda SK, Campagnolo D, Deutsch F, Arnold DL.

Mult Scler. 2008 Jun;14(5):663-70. doi: 10.1177/1352458507085759. Epub 2008 Apr 18.

PMID:
18424479
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk